Neurocrine Biosciences
NBIX
NBIX
367 hedge funds and large institutions have $7.91B invested in Neurocrine Biosciences in 2020 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 139 increasing their positions, 140 reducing their positions, and 63 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
367
Holders Change
-24
Holders Change %
-6.14%
% of All Funds
8.11%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.2%
New
42
Increased
139
Reduced
140
Closed
63
Calls
$62.4M
Puts
$53.4M
Net Calls
+$8.95M
Net Calls Change
-$28.1M
Top Buyers
| 1 |
HM
HealthCor Management
New York
|
+$64.1M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$56.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$49.6M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$43.9M |
| 5 |
JPMorgan Chase & Co
New York
|
+$36.2M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$62.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$47.5M |
| 3 |
Two Sigma Investments
New York
|
-$31.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$26.5M |
| 5 |
Millennium Management
New York
|
-$23.3M |
